Pernicious Anemia Diagnosis And Treatment Market Study Highlights How Industry Demand Is Evolving

Understanding the future landscape of the pernicious anemia diagnosis and treatment market reveals a sector poised for steady and significant expansion. Innovations in medical technology, coupled with evolving patient needs, are set to drive this industry's growth over the coming years. Let's delve into the market size projections, leading companies, prevailing trends, and the key segments defining this space.

Projected Size and Growth Trajectory of the Pernicious Anemia Diagnosis and Treatment Market
The market dedicated to diagnosing and treating pernicious anemia is anticipated to experience robust growth, reaching a valuation of $2.09 billion by 2030. This expansion is forecasted at a compound annual growth rate (CAGR) of 6.6%. Several factors contribute to this upward trend, including advancements in safer intravenous (IV) catheter technologies, greater adoption of smart and antimicrobial catheters, and the rapid expansion of home healthcare services. Additionally, growing preference for integrated and closed IV systems, along with an increase in minimally invasive therapy methods, are also key drivers. Emerging trends shaping this market during the forecast period include the growing use of AI-enabled catheter insertion guidance, cloud-based patient monitoring for IV therapy, development of smart and antimicrobial catheters, integration of Internet of Things (IoT) devices for IV monitoring, and the implementation of smart manufacturing processes for peripheral IV catheters.

The pernicious anemia diagnosis and treatment market size has grown strongly in recent years. It will grow from $1.51 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to high incidence of hospital-acquired infections, reliance on conventional iv catheters, growing patient population requiring iv therapy, limited availability of advanced safety catheters, fragmented healthcare infrastructure.

Download a free sample of the pernicious anemia diagnosis and treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Fueling Expansion in Pernicious Anemia Diagnosis and Treatment
One of the core elements propelling market growth is the enhancement of IV catheter safety and functionality. The introduction of antimicrobial and smart catheters is reducing infection risks and improving treatment outcomes, which is increasingly preferred by healthcare providers.
Simultaneously, the rise in home healthcare availability is expanding treatment options beyond traditional clinical settings. This shift allows patients to receive ongoing care in more comfortable environments, boosting demand for user-friendly and integrated treatment systems.

Major Industry Players Steering the Pernicious Anemia Market
The pernicious anemia diagnosis and treatment market features prominent pharmaceutical and medical technology companies, including Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc., Merck KGaA, Abbott Laboratories, Siemens Healthineers AG, Ortho Clinical Diagnostics Inc., Quest Diagnostics Incorporated, and Bio-Techne Corporation.
In a recent development, US-based investment firm Lightstone Group acquired Pfizer's clinical supply facility in Durham for $41.1 million in February 2025. This facility adds a move-in-ready, state-of-the-art cGMP clinical supply operation to their portfolio. Notably, Pfizer produces vitamin B12 capsules used in pernicious anemia treatment at this location.

View the full pernicious anemia diagnosis and treatment market report:
https://www.thebusinessresearchcompany.com/report/pernicious-anemia-diagnosis-and-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovative Trends Redefining Pernicious Anemia Management
Companies are increasingly focused on creating innovative vitamin B12 maintenance therapies aimed at improving patient adherence and effective long-term disease control. These therapies often involve consistent supplementation through oral tablets, injections, or nasal sprays to maintain adequate vitamin B12 levels and prevent recurrence of symptoms.
For example, in February 2024, Lupin Pharmaceuticals Inc., based in India, introduced a cyanocobalamin nasal spray (500 mcg per spray), offering a non-invasive alternative for vitamin B12 supplementation. This product is especially beneficial for patients who have difficulty with oral vitamin B12 forms, enhancing absorption and supporting more consistent management of vitamin B12 deficiency.

Detailed Segmentation Within the Pernicious Anemia Diagnosis and Treatment Market
The market segmentation covers several critical categories:
1) By Type of diagnostic test: Complete Blood Count Test, Vitamin B12 Deficiency Test, Intrinsic Factor Deficiency Test
2) By Treatment mode: Vitamin B12 Injections, Vitamin B12 Pills, Vitamin B12 Spray
3) By Route of Administration: Injection, Oral, Intranasal
4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-Users

Further subcategories include:
- Complete Blood Count (CBC) test details such as Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, and Platelet Count
- Vitamin B12 Deficiency tests including Serum Vitamin B12, Methylmalonic Acid (MMA), Homocysteine, and Holotranscobalamin (Active B12) tests
- Intrinsic Factor Deficiency tests such as Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, and Gastrin Level Test

These segments provide a comprehensive framework to understand the diagnostic and therapeutic approaches used in treating pernicious anemia.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.